AU2001271973A1 - Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis - Google Patents

Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Info

Publication number
AU2001271973A1
AU2001271973A1 AU2001271973A AU2001271973A AU2001271973A1 AU 2001271973 A1 AU2001271973 A1 AU 2001271973A1 AU 2001271973 A AU2001271973 A AU 2001271973A AU 2001271973 A AU2001271973 A AU 2001271973A AU 2001271973 A1 AU2001271973 A1 AU 2001271973A1
Authority
AU
Australia
Prior art keywords
diagnosis
compositions
treatment
methods
disorders involving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271973A
Other languages
English (en)
Inventor
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J Godowski
Austin L. Gurney
Kenneth J. Hillan
Scot A. Marsters
James Pan
Nicholas F. Paoni
Jean-Philippe F. Stephan
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Weilan Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/en
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/en
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/en
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,208 external-priority patent/US7217412B2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/en
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/en
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2001271973A1 publication Critical patent/AU2001271973A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001271973A 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis Abandoned AU2001271973A1 (en)

Applications Claiming Priority (73)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US60/219,556 2000-07-20
US22066400P 2000-07-25 2000-07-25
US22062400P 2000-07-25 2000-07-25
US60/220,664 2000-07-25
US60/220,624 2000-07-25
AU63910/00 2000-07-28
PCT/US2000/020710 WO2001009327A2 (en) 1999-07-28 2000-07-28 Method of preventing the injury or death of retinal cells and treating ocular diseases
US22269500P 2000-08-02 2000-08-02
US60/222,695 2000-08-02
US09/643,657 2000-08-17
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
PCT/US2000/023522 WO2001016319A2 (en) 1999-08-31 2000-08-23 Compositions and methods for the treatment of immune related diseases
AU70793/00 2000-08-23
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU75730/00 2000-08-24
US23097800P 2000-09-07 2000-09-07
US60/230,978 2000-09-07
US60/000,000 2000-09-15
US66461000A 2000-09-18 2000-09-18
US66535000A 2000-09-18 2000-09-18
US09/665,350 2000-09-18
US09/664,610 2000-09-18
US24292200P 2000-10-24 2000-10-24
US60/242,922 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (en) 2000-01-06 2000-11-08 Methods and compositions for inhibiting neoplastic cell growth
AU19167/01 2000-11-08
US09/709,238 2000-11-08
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
AU34346/01 2000-11-10
AU20554/01 2000-12-01
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
US09/747,259 2000-12-20
PCT/US2000/034956 WO2001046420A2 (en) 1999-12-23 2000-12-20 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
AU25909/01 2000-12-20
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US09/767,609 2001-01-22
US79649801A 2001-02-28 2001-02-28
AU2001268028 2001-02-28
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/796,498 2001-02-28
AU2001255168 2001-03-01
PCT/US2001/006666 WO2001066740A2 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases
US80270601A 2001-03-09 2001-03-09
US09/802,706 2001-03-09
US80868901A 2001-03-14 2001-03-14
US09/808,689 2001-03-14
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/816,744 2001-03-22
US09/828,366 2001-04-05
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/854,280 2001-05-10
US09/854,208 2001-05-10
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
PCT/US2001/017092 WO2001092331A2 (en) 2000-05-30 2001-05-25 Compositions and methods for the treatment of immune related diseases
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/866,034 2001-05-25
US09/866,028 2001-05-25
AU2001265019 2001-05-25
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/870,574 2001-05-30
PCT/US2001/017443 WO2002016611A2 (en) 2000-08-24 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
AU2001268108 2001-05-30
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
AU2001265311 2001-06-01
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852 2001-06-20
USPCT/US01/00000 2001-06-28
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Publications (1)

Publication Number Publication Date
AU2001271973A1 true AU2001271973A1 (en) 2002-02-05

Family

ID=56290165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271973A Abandoned AU2001271973A1 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Country Status (5)

Country Link
EP (1) EP1309685A2 (cg-RX-API-DMAC7.html)
JP (5) JP2004516013A (cg-RX-API-DMAC7.html)
AU (1) AU2001271973A1 (cg-RX-API-DMAC7.html)
CA (1) CA2416538A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002008284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837606T2 (de) 1997-09-12 2008-02-14 Biogen Idec Ma Inc., Cambridge Cystein-reiche rezeptoren-train
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
PT1200590E (pt) 1999-08-12 2009-03-24 Agensys Inc Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
EP1892249A1 (en) * 1999-09-01 2008-02-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3964678B2 (ja) 1999-10-28 2007-08-22 アジェンシス，インコーポレイテッド ３６ｐ６ｄ５：分泌腫瘍抗原
EP2290081A3 (en) * 1999-12-23 2012-08-01 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
CA2406884C (en) * 2000-04-21 2009-02-17 Fuso Pharmaceutical Industries, Ltd. Novel collectins
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) * 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) * 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CA2648051A1 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7164009B2 (en) 2000-09-15 2007-01-16 Genentech, Inc. Pro9821 polypeptides
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US20060141453A9 (en) 2000-11-03 2006-06-29 Qun-Yong Zhou Prokineticin polypeptides, related compositions and methods
AU2002217838A1 (en) 2000-11-14 2002-05-27 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells LSI-01
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003215761A1 (en) * 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2003220805A1 (en) * 2002-03-28 2003-10-13 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
KR20040101502A (ko) * 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003261911A1 (en) * 2002-09-04 2004-03-29 Takeda Pharmaceutical Company Limited Use of disease-associated gene
JP2006512903A (ja) * 2002-09-11 2006-04-20 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP2500438A3 (en) * 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
KR101118340B1 (ko) 2003-03-12 2012-04-12 제넨테크, 인크. 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
MXPA06011851A (es) 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.
SI1781682T1 (sl) 2004-06-24 2013-05-31 Mayo Foundation For Medical Education And Research B7-H5, so-stimulatorni polipeptid
ZA200610273B (en) 2004-07-02 2008-06-25 Genentech Inc Compositions and methods for treatment of non-hodgkin's lymphoma
EP2329714A1 (en) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Influence of TAJ in the neuronal functions
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP2010508819A (ja) 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗ｄ因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
EA201000844A1 (ru) * 2007-11-21 2011-10-31 Амген Инк. Связывающие wise агенты и эпитопы
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
AU2009245440C1 (en) 2008-05-05 2013-03-14 Novimmune Sa Anti-IL-17A/IL-17F cross-reactive antibodies and methods of use thereof
MX2010011372A (es) 2008-05-06 2010-11-12 Genentech Inc Variantes de crig de afinidad madurada.
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
AU2010244142B2 (en) 2009-05-05 2016-07-21 Novimmune Sa Anti-IL-17F antibodies and methods of use thereof
CA2760246A1 (en) 2009-05-08 2010-11-11 Weilan Ye Humanized anti-egfl7 antibodies and methods using same
AT508569A1 (de) 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
CN111875703B (zh) 2009-11-11 2024-06-04 安斯泰来制药股份有限公司 密蛋白6(cldn6)特异性的抗体
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2832174C (en) 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
HUE068364T2 (hu) * 2013-01-17 2024-12-28 Medizinische Hochschule Hannover Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
CN106662577B (zh) 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
GB201906052D0 (en) * 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8921598A (en) * 1997-08-29 1999-03-16 Human Genome Sciences, Inc. 29 human secreted proteins
JP2002506615A (ja) * 1998-02-27 2002-03-05 財団法人相模中央化学研究所 膜貫通ドメインを有するヒト蛋白質とそれをコードするｄｎａ
NZ507435A (en) * 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
JP2002509722A (ja) * 1998-03-31 2002-04-02 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
JP2003524599A (ja) * 1998-09-14 2003-08-19 ジェネンテック・インコーポレーテッド 血管新生と心血管新生の促進又は阻害
MXPA01005169A (es) * 1998-12-01 2002-07-02 Genentech Inc Promocion o inhibicion deangiogenesis y cardiovascularizacion.
AU2399300A (en) * 1999-03-08 2000-09-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
KR20030002292A (ko) * 1999-03-08 2003-01-08 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
CA2412211A1 (en) * 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Also Published As

Publication number Publication date
JP2009039117A (ja) 2009-02-26
JP2009039119A (ja) 2009-02-26
JP2004516013A (ja) 2004-06-03
JP6033531B2 (ja) 2016-11-30
WO2002008284A2 (en) 2002-01-31
JP2009039118A (ja) 2009-02-26
CA2416538A1 (en) 2002-01-31
WO2002008284A3 (en) 2003-03-13
JP2012005493A (ja) 2012-01-12
EP1309685A2 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AUPR101600A0 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
EP1315499A4 (en) COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU2215099A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
AU2002357675A1 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
AU2002359316A1 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 16319

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase